부갑상선 기능 저하증 시장 - 세계 및 지역별 분석 - 분석과 예측(2025-2035년)

Market Lifecycle Stage

The global hypoparathyroidism market is currently in the growth stage of its lifecycle. With increasing awareness of the condition and advancements in diagnostic technologies, the market is witnessing a rise in early diagnosis and treatment initiation. The development of new therapies, including novel parathyroid hormone treatments, has expanded the treatment options available for managing hypoparathyroidism, further fueling market growth. Additionally, the growing focus on rare diseases and personalized medicine, coupled with favorable regulatory support, has spurred investment in research and development, leading to the introduction of innovative therapies.

As healthcare access improves in emerging markets and treatment options become more widely available, the market is expected to continue its expansion. However, challenges such as high treatment costs and limited awareness in certain regions may impact the pace of growth. Overall, the global hypoparathyroidism market is positioned for continued growth with increasing therapeutic advancements and expanding global reach.

Impact

• Increasing demand for hypoparathyroidism therapies is anticipated to support the growth of the global hypoparathyroidism market during the forecast period 2025-2035.
• The global hypoparathyroidism market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline.

Recent Developments

• Regulatory Activities: In February 2025, Therapeutic Goods Administration approved Specialised Therapeutics' YORVIPATH for the treatment of chronic hypoparathyroidism in adults.
• Regulatory Activities: In August 2024, the FDA approved a once-daily parathyroid hormone prodrug for the treatment of adults with hypoparathyroidism.
• Partnerships: In July 2024, Pharmascience unit Pendopharm entered into an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Hypoparathyroidism
• Rising Awareness and Advancements in Diagnostic Technologies

Limitations:

• High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global hypoparathyroidism market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Specialised Therapeutics and Ascendis Pharma, have been involved in the development of therapies for hypoparathyroidism.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

• Ascendis Pharma
• AstraZeneca
• Bridgebio
• Entera Bio Ltd.
• MBX Biosciences, Inc.
• Specialised Therapeutics
• Visen Pharmaceuticals (Shanghai) Co., Ltd.

Table of Contents

Scope of Study

1. Global Hypoparathyroidism Market Overview

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Market Trend
  • 1.1.3 Epidemiological Analysis of Hypoparathyroidism
    • 1.1.3.1 By Region
      • 1.1.3.1.1 U.S.
      • 1.1.3.1.2 EU5
      • 1.1.3.1.3 Rest-of-the-World
  • 1.1.4 Clinical Trials
    • 1.1.4.1 By Phase
    • 1.1.4.2 By Sponsor Type
  • 1.1.5 Regulatory Landscape / Compliance
    • 1.1.5.1 Legal Requirement and Framework in the U.S.
    • 1.1.5.2 Legal Requirement and Framework in the E.U.
    • 1.1.5.3 Legal Requirement and Framework in Japan
    • 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
• 1.2 Market Dynamics
  • 1.2.1 Impact Analysis
  • 1.2.2 Market Drivers
  • 1.2.3 Market Restraints
  • 1.2.4 Market Opportunities

2. Global Hypoparathyroidism Market, By Region, $Million, 2023-2035

• 2.1 U.S.
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Hypoparathyroidism Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Rest-of-the-World
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast

3. Global Hypoparathyroidism Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Ascendis Pharma
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 AstraZeneca
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Bridgebio
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 MBX Biosciences, Inc.
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Entera Bio Ltd.
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Specialised Therapeutics
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Visen Pharmaceuticals (Shanghai) Co., Ltd.
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View

4. Research Methodology